RxDoctor Payments Data

Abas Amiry, MD

Cardiovascular Disease · Barrington, ILNPI 1982613006

Payments from drug & device makers

$1,466in general payments, 2019–2025

Across 49 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$389
  • Novartis$266
  • Boehringer Ingelheim$167
  • Esperion Therapeutics, Inc.$125
  • Merck$119
  • Sanofi-aventis U.S. LLC$102
  • plus $299 from 8 others

What the payments were for

  • Speaking & faculty fees$38927%
  • Food & beverage$1,06473%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,466 in reported general payments places this provider in the 45th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$99,287
Medicare patients
264
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$186,174
XareltoRivaroxaban65$68,967
Repatha SureclickEvolocumab67$66,282
EntrestoSacubitril/Valsartan41$65,989
JardianceEmpagliflozin15$16,739
Repatha SyringeEvolocumab17$9,365
FarxigaDapagliflozin Propanediol11$6,380
Metoprolol Succinate363$4,474
Nifedipine ErNifedipine74$4,089
Rosuvastatin Calcium205$2,407
Digoxin75$1,655
Amlodipine Besylate185$1,423
Bisoprolol Fumarate69$1,408
Midodrine Hcl47$1,403
Atorvastatin Calcium163$1,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$186,174146 claims
Johnson & JohnsonXarelto$17$68,96765 claims
NovartisEntresto$266$65,98941 claims
Boehringer IngelheimJardiance$167$16,73915 claims
AstraZenecaFarxiga$16$6,38011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →